FDA EIR - Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany - March 20, 2017

FDA EIR for Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany on March 20, 2017. Product: Drugs. Access full analysis and detailed observations.

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

FDA EIR for Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany on March 20, 2017. Product: Drugs. Access full analysis and detailed observations.

Violation Codes

21 CFR 211.100(a)

21 CFR 211.58

21 CFR 211.80(b)

21 CFR 211

21 CFR 211.115(a)

21 CFR 211.192

21 CFR 820.50

21 CFR 211.67(b)

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany

Inspection Date

March 20, 2017

Product Type

Drugs

Office

Center for Food Safety and Applied Nutrition

People

ID: bea5e98a-7d52-49f7-92d3-f6bee3c9ba28

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox